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Abstract
Fatty acid amide hydrolase (FAAH), the enzyme involved in the inactivation of the
endocannabinoid anandamide (AEA), is being considered as a therapeutic target for analgesia and
neuroprotection. We have developed a brain permeable FAAH inhibitor, AM5206, which has
served as a valuable pharmacological tool to explore neuroprotective effects of this class of
compounds. In the present work, we characterized the interactions of AM5206 with a
representative AEA carrier protein, human serum albumin (HSA), using 19F nuclear magnetic
resonance (NMR) spectroscopy. Our data showed that as a drug carrier, albumin can significantly
enhance the solubility of AM5206 in aqueous environment. Through a series of titration and
competitive binding experiments, we also identified that AM5206 primarily binds to two distinct
sites within HSA. Our results may provide insight into the mechanism of HSA-AM5206
interactions. The findings should also help in the development of suitable formulations of the
lipophilic AM5206 and its congeners for their effective delivery to specific target sites in the
brain.
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Introduction
The endocannabinoid system has been implicated as a therapeutic target for analgesia, antiemesis, and neuroprotection [1-3]. The blockade of fatty acid amide hydrolase (FAAH) can
lead to a chronic elevation of the endocannabinoid anandamide (AEA) levels at the synapse
[4,5]. Importantly, this produces few undesirable side effects typically associated with
tetrahydrocannabinol (THC), the active psychotropic ingredient in marijuana [6]. For this
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reason, selective FAAH inhibition offers an attractive strategy to obtain the beneficial
effects of CB1 receptor activation. Recently, it was reported that the cellular uptake of AEA
can be significantly potentiated by a class of anandamide carrier proteins such as albumin
and fatty acid binding proteins (FABPs) [7,8]. By inhibiting these anandamide carrier
proteins, the uptake of AEA inside the cell was found to be drastically reduced. These
findings provide a potential new therapeutic modality for neuroprotection through dual
inhibition of FAAH and anandamide carrier proteins.
In the course of developing potent and selective FAAH inhibitors, we have synthesized a
series of trifluoromethyl ketone analogs [9,10]. One of the most successful compounds,
AM5206 (1,1,1-trifluoro-5-[4-(benzyloxy)phenoxy]-2-pentanone, Figure 1), has served as a
valuable pharmacological tool to explore the neuroprotective effects of FAAH inhibition
[11-13]. It represents a new generation of reversible FAAH inhibitors that can cross the
blood brain barrier and protect against neurodegenerative changes and cytoskeletal damages.
To explore whether this class of FAAH inhibitors compete with AEA for binding to carrier
proteins, we have studied the interactions of several trifluoromethyl ketone analogs with
bovine serum albumin (BSA) [14]. We found that AM5206 has an affinity for serum
albumin approximately one order of magnitude higher than its congeners. In the present
communication, we reported a more detailed study of the interactions of AM5206 with
human serum albumin (HSA) as a representative anandamide carrier protein.
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Serum albumin has long been regarded as a carrier protein for various lipophilic endogenous
and exogenous compounds to their specific targets [15,16]. As a drug carrier, albumin is a
highly helical protein containing three homologous domains (I, II, and III), each consisting
of two subdomains (A and B) [17-19]. Two structurally selective drug-binding sites, which
are located in subdomains IIA and IIIA, are primarily associated with the delivery of various
drug molecules [20-22]. A number of biophysical techniques have been used to study the
interactions of ligands with albumin. These include fluorescence spectroscopy [23,24], gel
chromatography [25], high-performance liquid chromatography (HPLC) [26], electrospray
ionization mass spectrometry [27] and nuclear magnetic resonance (NMR). Although
fluorinated natural products are relatively rare, it was reported that approximately 25% of
drug molecules contain at least one fluorine atom [28]. For fluorine containing ligands, 19FNMR has been of particular interest due to the fact that 19F has 100% natural abundance
and 19F-signals are much more sensitive to changes in their chemical environment [29].
Additionally, because of the absence of fluorine atoms on proteins, the 19F-NMR spectra
from mixtures of fluorinated ligands and their target proteins are much simplified.
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In this work, we first employed 19F-NMR competition binding and titration experiments to
study the site-specific binding preference of AM5206 with human serum albumin using
warfarin, L-tryptophan and oleic acid [22,30,31] as site markers. We found that albumin can
drastically enhance the solubility of the lipophilic AM5206 in an aqueous environment. We
were also able to measure the exchange rates of AM5206 among these binding sites on
albumin using two dimensional (2D) 19F-NMR exchange spectroscopy (EXSY) experiments
[32]. The findings should help not only in elucidating the mechanism of HSA-AM5206
interactions, but also in developing suitable formulations for the effective delivery of
AM5206 and its congeners to specific target sites in the brain.

Materials and Methods
Materials
Fatty acid free human serum albumin (HSA) (purity 96%), warfarin sodium, L-tryptophan,
oleic acid, and 1 M HEPES buffer solution were purchased from Sigma-Aldrich (St. Louis,
MO) and used without further purification. The FAAH inhibitor AM5206 (Figure 1) was
J Pharm Pharmacol (Los Angel). Author manuscript; available in PMC 2014 February 12.
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synthesized in our laboratory and details of its synthesis will be published elsewhere.
Deuterium oxide (D2O) and deuterated dimethyl sulfoxide (DMSO) were purchased from
Cambridge Isotope Laboratories, Inc. (Cambridge, MA).
Sample preparation
Human serum albumin (HSA) was dissolved in 10 mM HEPES buffer solution with 100
mM NaCl, 0.05% sodium azide (NaN3), and 5% D2O. AM5206 and the competing site
markers warfarin, L-tryptophan and oleic acid were separately prepared in concentrated
stock solutions in DMSO-d6 or D2O. For all NMR samples, AM5206 was first added to
either the aqueous HEPES buffer or HSA solutions and the mixture was sonicated for 15
minutes in an ultrasonic water bath. In the competitive binding experiments, each of the
competing site markers was added consecutively from their respective stock solutions.
NMR measurement
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All 19F-NMR experiments were carried out at 376.5 MHz using a Bruker AvanceII 400MHz
NMR spectrometer using a 5 mm high-resolution BBFO probe. All spectra were recorded at
25°C using a 9.5-μs 90°-pulse and a 2-s repetition time without proton decoupling.
Deuterated trifluoroacetic acid (CF3COOD) was used as a standard for chemical shift
reference (-76.55 ppm). Two dimensional (2D) 19F-NMR exchange spectroscopy (EXSY)
experiments were conducted using the NOESYPH pulse sequence with a series of mixing
times from 0 to 100 ms. During the mixing time, signals can be transferred from one spin to
another. The intensities of all diagonal and cross peaks were measured using the Bruker
TOPSPIN software.

Results and Discussion
Site Selective Binding Characteristics of AM5206
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The 19F-NMR spectrum of AM5206 in HEPES buffer consists of a single sharp peak at
−86.18 ppm (Figure 2). However, when AM5206 was introduced into 0.6 mM HSA
solution, three major peaks at −83.86, −85.44, and −86.77 ppm and a minor peak at −87.95
ppm were observed, indicating that there are multiple binding sites for AM5206 on HSA. In
order to assign these peaks, we employed a series of competition binding experiments using
three well characterized site markers, warfarin, L-tryptophan and oleic acid. Warfarin binds
selectively to drug site 1 at subdomain IIA, while L-tryptophan is a typical ligand for drug
site 2 at subdomain IIIA [22,30,31]. These two sites are the major drug binding sites on
serum albumin. The naturally occurring ligand, oleic acid, can bind to a range of locations
on serum albumin with three high affinity sites, one at subdomain IB and the other two at
domain III. After adding 3 mM L-tryptophan, the minor peak at −87.95 ppm disappeared
completely. This suggests that a very small fraction of AM5206 binds to drug site 2 on
albumin and it can be displaced by L-tryptophan. In this same sample, when we added 3
mM warfarin, the signal at −86.77 ppm disappeared completely indicating that this peak
arises from AM5206 binding to drug site 1 at subdomain IIA. With the addition of these two
major drug site markers, the resonance at −85.44 ppm increased significantly. Upon further
addition of 3 mM oleic acid, the signal at −83.86 ppm was partially reduced accompanied by
a broadening and further increase of the peak at −85.44 ppm. We therefore assigned the –
83.86 ppm peak to AM5206 binding at the fatty acid sites (FA sites) on albumin. The
resonance at −85.44 ppm could be most probably attributed to non-specific binding of
AM5206 to albumin.
To further explore the binding characteristics of AM5206 with human serum albumin, we
performed a series of titration experiments by adding AM5206 to 0.6 mM HSA solution.
Figure 3 shows the 19F-NMR spectra with various HSA to AM5206 ratios. At HSA:
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AM5206 molar ratios of 1:0.25 and 1:0.5, only one single peak at −83.86 ppm was
observed. This shows that the fatty acid sites (FA sites) on albumin are easily accessible by
AM5206 at low concentrations. At a ratio of 1:1, a peak at −86.77 ppm started appearing.
With further additions of AM5206, the resonances at −85.44 and −87.95 ppm also started to
appear. At a HSA: AM5206 ratio of 1:5, the signal at −85.44 ppm is ~10× stronger than all
other peaks, thus providing additional evidence that this −85.44 ppm peak is due to nonspecific binding of AM5206 to HSA. In our earlier study of AM5206 with BSA, the 19F
signal from AM5206 at drug site 1 and non-specific site coalesce due to fast exchange.
Conversely, in our HSA experiments, the −86.77 ppm (drug site 1) and −85.44 ppm (nonspecific binding) peaks remained separate over the entire course of our titration experiments,
suggesting a tight binding of AM5206 to HSA compared to BSA [14]. Additionally, at all
HSA:AM5206 ratios, no peak was observed at −86.18 ppm due to free AM5206 in solution,
suggesting a fast exchange with the non-specific binding sites. Parallel NMR titration
experiments were also conducted by adding the same amounts of AM5206 to HEPES buffer
solution only. As shown in Figure 3, there was only one single sharp peak at −86.18 ppm
due to free AM5206 in solution. The intensity of this peak remains virtually unchanged as
the added amount of AM5206 stock increases from 1.5μL to 30 μL. No additional peak was
observed due to any undissolved AM5206.
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It is interesting to compare the integrations of the 19F-NMR spectra from these two parallel
titration experiments. Since NMR detects only the “soluble” fraction of AM5206 in all
sample preparations, it presents a unique methodology to quantify its solubility [33-35]. To
ensure accurate integration, we first measured the integrals of different 19F-NMR spectra
recorded using a range of recycle delays from 1 s to 30 s and confirmed that a 2 s recycle
delay between scans is adequate. In Figure 4, we plotted the total integral values against the
amount of AM5206 added in each NMR sample. When titrated into the HSA solution, the
integral values increased linearly with the addition of AM5206. The black line represents the
best-fit of the data points according to the linear regression model, and the r2 is found to be
0.993. Our data show that albumin can completely solubilize AM5206 up to 1.0 mg/ml
concentration (30 μl AM5206 stock in 500 μl HSA solution). This corresponds to a 3.0 mM
of AM5206 concentration in the HSA solution. In contrast, when AM5206 was added into
HEPES buffer, the signal integral increased at the very beginning and leveled off for the
remaining titration experiments. This corresponds to an AM5206 concentration of ~70 μM
in the HEPES buffer solution. Therefore, albumin can significantly enhance the solubility of
AM5206 in aqueous buffer solutions from ~70 μM to 3.0 mM, an approximately 50-fold
increase.
Exchange of AM5206 among different binding sites
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Spectral line shape analysis has been commonly used to study chemical exchange process.
However, it is essentially limited to two-site exchange systems [36]. Two-dimensional
exchange spectroscopy (EXSY) NMR experiments provide an excellent approach to
investigate slow exchange process among different sites [37]. In order to determine the
exchange rates for AM5206 among the different binding sites on HSA, 2D 19F-EXSY
spectra were collected with mixing time tm ranging from 0 to 100 ms. (Figure 5) shows two
representative EXSY spectra of AM5206 in HSA solution at a HSA: AM5206 molar ratio of
1:2. The minor signal at −87.95 ppm in 1D 19F-NMR spectrum was too weak to be observed
in the 2D EXSY spectra. When tm=0 (no mixing), only three diagonal peaks were observed.
As assigned earlier, peaks #1 (−83.86 ppm), #2 (−85.44 ppm), and #3 (−86.77 ppm) are due
to AM5206 in fatty acid binding site(s), in the non-specific binding sites, and in drug site 1,
respectively. When tm was gradually increased, six cross-peaks started to emerge and their
intensities increased at the expense of the diagonal peak intensities, which is direct evidence
for exchange among these three types of binding sites. We used the relative intensities of
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diagonal and cross peaks to quantitatively analyze the exchange rate constants among the
three main sites identified in the 2D 19F-EXSY spectra [37,38]. The intensities of these nine
peaks are given as functions of mixing time tm,
(1)

where Ijj (0) are intensities of the three diagonal peaks at tm=0, R is a 3×3 matrix containing
the pseudo first-order exchange rate constants kij and the spin-lattice relaxation time T1.
Specifically,

(2)

It is not trivial to calculate the exponential of the R matrix since it is non-diagonal and
asymmetric. It must be calculated by the following series expansion (we used 80 terms in
the series), and Rn is the matrix multiplication of R by itself n times:
(3)
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To simplify calculations, we assumed that AM5206 at these three sites have the same T1
value and used the fact that the pairs of exchange rate constants are related by relative
populations as measured by Ijj(0):
(4)

Therefore, there were only four adjustable parameters in R, namely, k21, k13, k23, and T1.
Figure 6 shows simultaneous fits of the three diagonal peaks and the three pairs of cross
peaks using the following parameters: k21 = 115 s−1, k13 = 1 s−1, k23 = 47 s−1, and T1 = 0.5
s.
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Among these three diagonal peaks, we found that with the increase of tm, the −85.44 ppm
(peak #2) exhibited a much faster decay than the other two diagonal peaks; consistent with
our assignment that this peak represents the non-specific binding of AM5206. As for the
cross peaks, we found that the 1-3 and 3-1 pair, which is due to exchange between fatty acid
sites and drug site 1, has a much smaller initial slope than all the other cross-peaks. This
observation clearly indicated that the exchange between these two specific binding sites is
much slower than exchanges involving the non-specific sites. Our calculated exchange rate
constants showed that k13 is indeed almost two orders of magnitude smaller than either k21
or k23.
In the aqueous buffer solution, AM5206 has very low solubility (~70 μM) and it aggregates
rapidly into various forms or even precipitates out of solution (Figure 7A). The addition of
serum albumin can drastically increase the solubility of AM5206 and potentially dissolve all
the aggregates. We now propose the following two different binding scenarios of AM5206
due to the multiple binding sites on human serum albumin. With low content of AM5206
(HSA:AM5206 ratio up to 1:0.5), it almost binds exclusively at the fatty acid binding site(s)
on albumin (Figure 7B). This is probably because of the easy accessibility of some of the FA
sites, particularly the FA site on subdomain IB which is the most open of all the presumed
high-affinity pockets on HSA [18]. When higher amount of AM5206 is present in HSA
J Pharm Pharmacol (Los Angel). Author manuscript; available in PMC 2014 February 12.
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solution, it starts to interact with many other different binding sites on albumin while
AM5206 undergoes slow exchange among these binding sites (Figure 7C). Specifically, the
exchange rates are 115 s-1 and 47s-1 for AM5206 to dissociate from the non-specific sites to
the fatty acid site(s) or drug site 1, respectively. However, the exchange rate of AM5206
between the two specific binding sites (fatty acid site(s) and drug site 1) is ~1 s-1, almost
two orders of magnitude smaller than those involving the non-specific binding sites. This
observed spectroscopic exchange can be explained through a direct transfer of AM5206
between fatty acid site(s) and drug site 1. This very slow process is also compatible with an
alternative explanation according to which AM5206 undergoes exchanges indirectly through
the intermediacy of the non-specific sites. As for AM5206 at the non-specific sites, there
exists a fast exchange with the free AM5206 present in the HSA solution. The more
AM5206 added into the HSA solution, the more it associates directly to the non-specific
binding sites. In the present study, the non-specific binding sites are not saturable over the
entire titration experiments with HSA:AM5206 ratios up to 1:5. The complexity of the
binding scenarios of serum albumin, in conjunction with the poor aqueous solubility of
ligands, underscores the difficulty of obtaining accurate dissociation constants for each of
the binding sites. This helps explain the frequent discrepancies of reported affinity values of
drug molecules with albumin in the literature.

Conclusions
NIH-PA Author Manuscript

The interactions between a selective FAAH inhibitor AM5206 and human serum albumin
have been studied using 19F NMR technique. The primary binding sites for AM5206 are
drug site 1 located at subdomain IIA as well as fatty acid site(s) at subdomain IB and domain
III. With excess amount of AM5206 added, it tends to associate with many of the nonspecific binding sites on albumin. This drastically increases the aqueous solubility of
AM5206. To further understand the binding events, we have also determined the exchange
rates of AM5206 among various binding sites on HSA. Comparing to our earlier results with
BSA, AM5206 has a much tighter binding to drug site 1 on human serum albumin. It has
been demonstrated that the endocannabinoid anandamide also binds to HSA. It can thus be
argued that AM5206 may compete with anandamide for HSA binding. The result of such a
potential competition would be the enhancement of free anandamide levels. We conclude
that in addition to its role as a FAAH inhibitor, AM5206 may further enhance its effects
through the release of anandamide from HSA. We are now in the process of identifying the
specific sites for anandamide binding with HSA. Further experiments are also underway to
examine whether AM5206 can compete effectively with anandamide for binding with
albumin.
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AEA

N-arachidonoylethanolamine, anandamide

FAAH

Fatty Acid Amide Hydrolase

HSA

Human Serum Albumin
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Figure 1.

Structure of the trifluoromethyl ketone FAAH inhibitor AM5206.
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Figure 2.
19F-
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NMR spectra of 0.6 mM AM5206, with 0.6 mM human serum albumin (HSA), and in
the presence of one, two, or three of the competing site markers L-tryptophan, warfarin
sodium and oleic acid.
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Figure 3.

Left: 19F- NMR titration experiments of AM5206 into 0.6 mM HSA solution. Right: 19FNMR spectra by adding the same amounts of AM5206 stock solution (50 mM in DMSO)
into 500 μL HEPES buffer. The ligand concentrations listed in each spectrum reflect the
soluble fraction of AM5206 as obtained by integrating the 19F-NMR signals (cf. Figure 4).
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Figure 4.
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Integration of 19F-NMR signals from AM5206 in HEPES buffer with HSA (blue squares)
and without HSA (red circles). The two horizontal axes represent the actual amount of
AM5206 stock solution (50 mM in DMSO) added and the corresponding amount of
AM5206 in the NMR sample (mg/mL). The vertical axis on the right shows the
concentration of the soluble portion of AM5206.
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Figure 5.
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19F

EXSY spectra of 1.2 mM AM5206 with 0.6 mM HSA in HEPES buffer. Left panel:
mixing time tm = 0. Right panel: tm = 30 ms.
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Figure 6.

Different peak intensities as functions of mixing time tm. Top panels: three diagonal peaks.
Bottom panels: three pairs of cross peaks. The solid lines represent calculated results using
exchange rate constants k21=115 s−1, k13=1 s−1, k23=47 s−1, and spin-lattice relaxation time
0.5 s.
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Figure 7.
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Proposed binding scenarios and the mechanism for the solubility enhancement by HSA: (A)
In the aqueous buffer solution, AM5206 has a very low solubility (~70 μM), and most of it
forms aggregates or even precipitates. (B) With HSA present, a fast exchange allows
AM5206 to rapidly bind to the fatty acid binding site(s) and to dissolve the aggregated/
precipitated AM5206. (C) More binding sites (namely, drug site 1 and non-specific binding
sites) on HSA become available at higher concentrations of AM5206. The exchange rate
constants among these binding sites are indicated in the diagram.

J Pharm Pharmacol (Los Angel). Author manuscript; available in PMC 2014 February 12.

